Arrowhead Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on March 19, 2026, where several key proposals were presented for a vote. The company reported that a total of 119,801,542 shares were present, either in person or by proxy, out of 140,010,690 shares outstanding. The proposals included the election of seven directors to the Board, an advisory vote on executive compensation, approval of the Amended and Restated 2021 Incentive Plan, and the ratification of KPMG LLP as independent auditors for the fiscal year ending September 30, 2026.

The election of directors was successful, with all nominees receiving a majority of votes in favor. However, the advisory vote on executive compensation did not pass, with 41,625,740 votes in favor and 59,963,903 against. The approval of the Amended and Restated 2021 Incentive Plan was passed with 99,158,276 votes for and 2,401,793 against. The ratification of KPMG LLP as auditors was overwhelmingly approved with 119,053,168 votes in favor.

The results reflect a strong support for the board's nominees and the incentive plan, despite the setback with the executive compensation proposal. This meeting is a critical moment for Arrowhead as it continues to navigate its strategic direction and operational execution in the biopharmaceutical sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.